Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Item No. 11093

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Cannabinoids (CBs) and their synthetic analogs produce biochemical and pharmacological effects by interacting with the central CB1 and peripheral CB2 receptors. The CB2 receptor has emerged as a pharmacotherapeutic target for treating osteoporosis, as well as for eliciting antinociceptive effects in various models of pain. 4-Quinolone-3-carboxamide CB2 ligand is a selective, high-affinity ligand of the CB2 receptor, displaying a Ki value of 0.6 nM (Ki >10,000 nM for CB1) in vitro. At a dose of 6 mg/kg, 4-quinolone-3-carboxamide CB2 ligand exhibits antinociceptive activity in a formalin test of nocifensive response in mice. This analgesic affect is not significantly reversed by the CB2 antagonist AM630 (Item No. 10006974), which suggests 4-quinolone-3-carboxamide CB2 ligand may behave as an inverse agonist.1
WARNING This product is not for human or veterinary use.
1. Investigations on the 4-